Sep. 8 at 1:12 PM
$INTC $NVS $SGML $PTON $BSX
PRE-MARKET MOVERS:
Currently Higher:
- Roivant Sciences (ROIV) up 19.1% after reporting its PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease met primary and secondary endpoints
- Pharavis (PHVS) up 19.6% after announcing that the primary endpoint and all secondary efficacy endpoints were met in the CHAPTER-3 study evaluating deucrictibant extended-release tablet for the prevention of hereditary angioedema attacks
- IonQ (IONQ) up 5.7% after providing FY26 revenue update and agreement with Congruity360
- Rigetti Computing (RGTI) up 6.6% after signing a definitive agreement with the U.S. Department of Commerce for an award of
$100M in funding to accelerate superconducting quantum computing R&D
- Herbalife (HLF) up 2.6% after authorizing the repurchase of up to
$250M in shares
- Intel (INTC) up 4.9% following report company plans to raise CPU prices
Currently Lower:
- Novartis (NVS) down 12.7% after reporting that the global Phase 3 HARBOR study evaluating del-desiran in people living with myotonic dystrophy type 1 did not demonstrate statistically significant improvement versus placebo on the primary endpoint of video hand opening time
- Sigma Lithium (SGML) down 12.9% after a preliminary judicial ruling suspending its environmental licenses
- Peloton (PTON) down 5.4% after Morgan Stanley downgraded the stock to Underweight with a price target of
$4.50, down from
$5
- Boston Scientific (BSX) down 1.0% after saying it is unlikely to meet EPS and sales guidance following a cybersecurity incident that resulted in a global disruption to the company's operations.
